Literature DB >> 24073141

The Society of Behavioral Medicine position statement on the CMS decision memo on intensive behavior therapy for obesity.

Sherry L Pagoto1, Lori Pbert, Karen Emmons.   

Abstract

In 2011, the Centers for Medicare and Medicaid Services (CMS) issued a decision to cover intensive behavior therapy for obesity in the primary care setting. The Society of Behavioral Medicine (SBM) Public Policy Leadership Group reviewed the CMS decision and has issued a position statement. SBM is in support of the CMS decision to cover intensive behavior therapy for obesity but expresses significant concern that aspects of the decision will severely limit the impact of the decision. Concerns focus on the degree to which this care can be feasibly implemented in its current form given the limitations in providers who are covered and the short length of counseling visits relative to evidence-based protocols. SBM is in strong support of modifications that would include providers who have expertise in weight control (e.g., psychologists and dietitians) and to expand the treatment time to better match protocols with confirmed efficacy.

Entities:  

Keywords:  Behavioral interventions; Obesity; Policy; Weight loss

Year:  2012        PMID: 24073141      PMCID: PMC3717932          DOI: 10.1007/s13142-012-0168-x

Source DB:  PubMed          Journal:  Transl Behav Med        ISSN: 1613-9860            Impact factor:   3.046


  6 in total

1.  Primary care--will it survive?

Authors:  Thomas Bodenheimer
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

2.  Changes in medical students' views of internal medicine careers from 1990 to 2007.

Authors:  Mark D Schwartz; Steven Durning; Mark Linzer; Karen E Hauer
Journal:  Arch Intern Med       Date:  2011-04-25

3.  The Diabetes Prevention Program (DPP): description of lifestyle intervention.

Authors: 
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

4.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

5.  Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.

Authors:  Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski
Journal:  Control Clin Trials       Date:  2003-10

6.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

  6 in total
  7 in total

1.  Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristics.

Authors:  Peter T Katzmarzyk; Corby K Martin; Robert L Newton; John W Apolzan; Connie L Arnold; Terry C Davis; Kara D Denstel; Emily F Mire; Tina K Thethi; Phillip J Brantley; William D Johnson; Vivian Fonseca; Jonathan Gugel; Kathleen B Kennedy; Carl J Lavie; Eboni G Price-Haywood; Daniel F Sarpong; Benjamin Springgate
Journal:  Contemp Clin Trials       Date:  2018-02-08       Impact factor: 2.226

Review 2.  The Effect of Obesity and Chronic Conditions on Medicare Spending, 1987-2011.

Authors:  Lindsay Allen; Ken Thorpe; Peter Joski
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

Review 3.  Enhancing the Evidence for Behavioral Counseling: A Perspective From the Society of Behavioral Medicine.

Authors:  Carmela Alcántara; Lisa M Klesges; Ken Resnicow; Amy Stone; Karina W Davidson
Journal:  Am J Prev Med       Date:  2015-09       Impact factor: 5.043

Review 4.  Designation of obesity as a disease: lessons learned from alcohol and tobacco.

Authors:  Ryan T Hurt; Jithinraj Edakkanambeth Varayil; Manpreet S Mundi; Robert G Martindale; Jon O Ebbert
Journal:  Curr Gastroenterol Rep       Date:  2014-11

5.  Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.

Authors:  John W Apolzan; Elizabeth M Venditti; Sharon L Edelstein; William C Knowler; Dana Dabelea; Edward J Boyko; Xavier Pi-Sunyer; Rita R Kalyani; Paul W Franks; Preethi Srikanthan; Kishore M Gadde
Journal:  Ann Intern Med       Date:  2019-04-23       Impact factor: 25.391

6.  Weight Loss in Underserved Patients - A Cluster-Randomized Trial.

Authors:  Peter T Katzmarzyk; Corby K Martin; Robert L Newton; John W Apolzan; Connie L Arnold; Terry C Davis; Eboni G Price-Haywood; Kara D Denstel; Emily F Mire; Tina K Thethi; Phillip J Brantley; William D Johnson; Vivian Fonseca; Jonathan Gugel; Kathleen B Kennedy; Carl J Lavie; Daniel F Sarpong; Benjamin Springgate
Journal:  N Engl J Med       Date:  2020-09-03       Impact factor: 91.245

7.  Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors: A Cluster-Randomized Trial.

Authors:  Christoph Höchsmann; James L Dorling; Corby K Martin; Robert L Newton; John W Apolzan; Candice A Myers; Kara D Denstel; Emily F Mire; William D Johnson; Dachuan Zhang; Connie L Arnold; Terry C Davis; Vivian Fonseca; Carl J Lavie; Eboni G Price-Haywood; Peter T Katzmarzyk
Journal:  Circulation       Date:  2021-02-09       Impact factor: 29.690

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.